SCHEMBL11252152

SCHEMBL11252152

CS(=O)(=O)OCCCC1CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.58
ALDH1A1 P00352 2/20 0.58
USP2 O75604 2/20 0.58
LMNA P02545 2/20 0.58
KDM4E B2RXH2 1/20 0.58
MMP9 P14780 1/20 0.58
ALOX15 P16050 1/20 0.58
GPR119 Q8TDV5 3/20 0.33
RECQL P46063 2/20 0.32
MAPK1 P28482 2/20 0.32
GLA P06280 1/20 0.32
HPGD P15428 1/20 0.32
EPHX2 P34913 1/20 0.32
BLM P54132 1/20 0.32
CYP1A2 P05177 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
HTT P42858 1/20 0.32
CA1 P00915 4/20 0.31
CA2 P00918 4/20 0.31
CA9 Q16790 3/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7220330 0.94 TSHR (0.62) TSHRALDH1A1USP2LMNAKDM4E
SCHEMBL2766625 0.92 ALDH1A1 (0.54) TSHRALDH1A1USP2LMNAKDM4E
SCHEMBL2766649 0.90 KDM4E (0.52) TSHRALDH1A1USP2LMNAKDM4E
SCHEMBL4400027 0.87 KDM4E (0.48) TSHRALDH1A1USP2LMNAKDM4E
SCHEMBL6495440 0.87 ALDH1A1 (0.48) TSHRALDH1A1USP2LMNAKDM4E
SCHEMBL31704435 0.87 TSHR (0.54) TSHRALDH1A1USP2LMNAKDM4E
SCHEMBL1613295 0.86 USP2 (0.50) TSHRALDH1A1USP2LMNAKDM4E
Hydrochloric Acid SCHEMBL6018852 0.86 KDM4E (0.44) TSHRALDH1A1USP2LMNAKDM4E
Hydrochloric Acid SCHEMBL6018849 0.86 KDM4E (0.44) TSHRALDH1A1USP2LMNAKDM4E
SCHEMBL23292770 0.86 TSHR (0.58) TSHRALDH1A1USP2LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034094-A1 COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS KOJIN THERAPEUTICS INC (US) 2026-02-05 US disclosed
EP-4565228-A2 COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS Kojin Therapeutics, Inc. (US) 2025-06-11 EP disclosed
WO-2024030960-A2 COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS Kojin Therapeutics, Inc. (US) 2024-02-08 WO disclosed
WO-2008127734-A2 LYSINE-SPECIFIC DEMETHYLASE INHIBITORS THE JOHNS HOPKINS UNIVERSITY (US) 2008-10-23 WO disclosed
US-4311708-A ADRENERGIC BLOCKING AGENTS SYNTHELABO (FR) 1982-01-19 US disclosed
US-4252984-A 1-/P-/2-/CYCLOPROPYLMETHOXY/ETHYL/PHENOXY/-3-ISOPROPYLAMINO-2 -PROPANOL SYNTHELABO (FR) 1981-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034094-A1 COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS AIFM2, GPX4, HMOX1 TSHR 699/4885ALDH1A1 3274/4885USP2 2346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.